Prof. Qiang Gao 高强
Chief Physician, Professor
Department of Hepatobiliary Oncology and Liver Transplantation, Zhongshan Hospital, Fudan University, Shanghai
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Benign and malignant liver and biliary tumors, gallbladder and bile duct diseases, metastatic liver cancer, minimally invasive liver surgery, and liver transplantation.
Dr. Gao is Director of the Department of Hepatobiliary Tumors and Liver Transplantation at Zhongshan Hospital, Fudan University. A Changjiang Scholar and National Ten Thousand Talents Program member, Dr. Gao focuses on personalized comprehensive treatment for hepatobiliary tumors. Research has been published in Cell, Science, Annals of Oncology, and Journal of Clinical Oncology. Honors include the Second Prize of National Science and Technology Progress Award.
Professional roles
- Chair, Hepatobiliary Youth Working Group, Surgical Branch of Chinese Medical Doctor Association
- Member and Secretary, Liver Cancer Quality Control Committee, National Cancer Center
- Vice Chair, Cell Immunotherapy Committee, China Health Promotion Association
- Standing Committee Member, Integrated Prevention and Screening Committee for Liver Cancer, China Anti-Cancer Association
Name order: in Chinese the family name comes first (Gao Qiang). Papers usually list the name as Qiang Gao or Gao Q.
Selected publications
242 papers on PubMed matched by name and affiliation; 65 as first or senior author since 2016. Most recent first- or senior-author papers:
- Cancer Discov, 2026 (senior author): Arachidonic Acid Metabolism in PMN-MDSCs Suppresses Antitumor Capacity of T Cells in KRAS-Mutant Cholangiocarcinoma. PubMed 41949259
- Cancer Cell, 2026 (senior author): OpenIO: An open framework for AI-native immunotherapy. PubMed 42349428
- Cancer Lett, 2026 (senior author): Targeting MUC16 suppresses malignant progression and chemoresistance in large-duct type intrahepatic cholangiocarcinoma. PubMed 41839437
- Cancer Innov, 2026 (senior author): Global Advances in Hepatocellular Carcinoma Research and Therapy in 2025. PubMed 42005557
- Cell Res, 2025 (senior author): Harnessing alternative splicing for off-the-shelf mRNA neoantigen vaccines in hepatocellular carcinoma. PubMed 41315871
- Cancer Lett, 2025 (senior author): Mapping the tumor immune landscape: single-cell RNA sequencing in cancer immunotherapy. PubMed 40889736
- Exp Hematol Oncol, 2025 (senior author): Correction: Multi-model analysis of gallbladder cancer reveals the role of OxLDL-absorbing neutrophils in promoting liver invasion. PubMed 41194180
- Hepatol Commun, 2025 (senior author): Omics-driven networks herald a new era of multidimensional therapy for cholangiocarcinoma. PubMed 40906890
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion